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IADPSG criteriaAims: Quantify the proportional increase in gestational diabetes (GDM) prevalence when
implementing the new International Association of Diabetes and Pregnancy Study Groups
(IADPSG) criteria compared to prior GDM criteria, and to assess risk factors that might
affect the change in prevalence.
Methods: A systematic review and meta-analysis was performed of cohort and cross-
sectional studies between January 1, 2010 to December 31, 2018 among pregnant women
with GDM using IADPSG criteria compared to, and stratified by, old GDM criteria. Web of
science, PubMed, EMBASE, Cochrane, Open Grey and Grey literature reports were included.
The relative risk for each study was calculated. Subgroup analyses were performed by
maternal age, body mass index, study design, country of publication, screening method,
sampling method and data stratified according to diagnostic criteria.
Results: Thirty-one cohort and cross-sectional studies with 136 705 women were included.
Implementing the IADPSG criteria was associated with a 75% (RR 1.75, 95% CI 1.53–2.01)
increase in number of women with GDM with evidence of heterogeneity.
Conclusions: The IADPSG criteria increase the prevalence of GDM, but allow movement
towards more homogeneity. More studies are needed of the benefits, harms, psychological
effects and health costs of implementing the IADPSG criteria.
 2020 The Author(s). Published by Elsevier B.V. This is an open access article under theCC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Gestational diabetes mellitus (GDM) was defined by O’Sulli-
van as ‘‘carbohydrate intolerance of varying severity with
onset or first recognition during pregnancy” [1]. This firstOral glucose tolerance test (OGTT) based criteria for GDM
were chosen to identify women with a high future risk of
developing type 2 diabetes mellitus [2]. Since this time, a
variety of diagnostic approaches to GDM have been devel-
oped across the world.o, Sweden.
2 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 2 ( 2 0 2 1 ) 1 0 8 6 4 2GDM is associated with several long- and short-term
adverse outcomes for the mother (Shoulder dystocia, pre-
eclampsia, cesarean section, type 2 diabetes mellitus, meta-
bolic syndrome, cardiovascular disease) [3–5] and child
(macrosomia, birth trauma, neonatal hypoglycemia, impaired
glucose tolerance, metabolic syndrome, cardiovascular dis-
ease) [5–7]. There is a clinical importance to finding women
with GDM, since many short term adverse outcomes can be
reduced with GDM treatment (lifestyle and diet, metformin,
insulin) [8,9].
Internationally, theprevalenceofGDMvaries from1 to 28%.
Even if the same diagnostic criteria and screening method are
applied, the prevalence of GDM varies depending on popula-
tion characteristics such as age, ethnicity, overweight/obesity,
lifestyle (physical activity, diet) and type 2 diabetes mellitus
prevalence in the background population [10–14].
In 2010, the International Association of Diabetes and
Pregnancy Study Groups (IADPSG) consensus panel outlined
new diagnostic criteria for GDM, which were for the first time,
based on adverse pregnancy outcomes [15]. In 2013 the World
Health Organization (WHO) adopted the IADPSG criteria,
defined during a 75 g OGTT at an adjusted threshold of 175
times odds ratio for adverse pregnancy outcomes with glu-
cose concentration cut-offs of fasting  51, 1-hour  100
and/or 2-hour  85 mmol/l.
As a consequence of the new consensus based criteria
with lower fasting cut-off values, added one-hour value, one
value sufficient for diagnosis and using a one-step method
(diagnostic test only) instead of screening, the GDM preva-
lence was reported to increase 2–11 fold compared to baseline
criteria [10,15–17]. This is in alignment with the increasing
prevalence of the pandemic of obesity and associated
increase in diabetes in the world, especially in young adults
[18–20]. These increases in GDM numbers have raised con-
cerns on the impact on the healthcare system, health out-
comes, quality of life and costs.
With ongoing debate about implementing the internation-
ally recommended IADPSG criteria, there is a need for an
updated estimation of the increase in prevalence of GDM
when implementing the IADPSG criteria. The aim of this com-
prehensive systematic review and meta-analysis was to
quantify the overall increase in GDM prevalence when imple-
menting the new IADPSG criteria compared to old GDM crite-
ria, and to assess any contribution by risk factors that might
affect the prevalence.
2. Material and methods
2.1. Search strategy and selection criteria
This systematic review and meta-analysis were conducted
based on the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) guidelines [21].
A literature search was conducted from January 1st 2010 to
December 31th 2018 using Web of science, PubMed, EMBASE,
Cochrane, Open Grey and Grey literature report, by librarians
and investigators. MeSH terms including ‘‘gestational dia-
betes”, ‘‘pregnancy induced diabetes”, ‘‘hyperglycemia”, ‘‘glu-
cose intolerance”, ‘‘insulin resistance‘‘, ”prevalence” and‘‘incidence” were used alone or in combination (Supplemen-
tary Table 1).
All original population-based publications involving preg-
nant women with GDM according to IADPSG (intervention)
criteria and at least one other GDM criterion (control) were
eligible. The same screening strategy for GDM needed to be
used both during the preceding control period and after the
introduction of the IADPSG criteria. The time between the
old GDM criteria and implementation of the new GDM criteria
had to be less than one year. Duplicated data, non-English
publications, intervention studies, inadequate methodology
description and studies prior to 2010 were excluded.
The outcome studied was the overall increase in GDM
according to the IADPSG criteria compared with any older cri-
teria using a 75 g OGTT (Table 1). The WHO 1999 criteria for
GDM were used as the control if available. If data for
WHO1999 GDM criteria were missing, an alternative older
set of GDM criteria was used. The GDM criteria resulting in
the highest frequency of GDM was used if several older crite-
ria existed.
The study was registered on PROSPERO (CRD42018088703)
[22].
2.2. Data extraction and analysis
Screening of titles and abstracts was performed indepen-
dently by two investigators (MS and HG) using Rayyan web
tool [23]. Disagreements were resolved through discussion
with senior investigators (DS and HF). Data on study charac-
teristics as authors name, publication year, study design,
sample size, mean age, mean body mass index (BMI), country
of study, ethnicity (minority/indigenous), rural/urban, popu-
lation origin, study period, screeningmethod (early screening,
risk factor, two step, universal), prevalence of GDM according
to IADPSG criteria and other GDM criteria usedwere extracted
and tabulated. If more than one report related to the same
cohort, the report with the most relevant information was
included. Control checks for agreement of final data extrac-
tion files and studies were made (MS and HG).
The methodological quality of the cohort studies was ana-
lyzed independently by two investigators (MS and HG) using
the Newcastle Ottawa scale studies [24], which assesses three
main domains: selection, comparability, and outcome (Sup-
plementary Tables 2 and 3). Studies were considered high-,
medium-, or low quality with a score above six, three to six
and less than three respectively (Table 2).
Summary relative risks (RRs) with 95% confidence inter-
vals (CI) were calculated using random-effects models. Forest
plots was used to visualize the extent of heterogeneity
between studies. Statistical heterogeneity between studies
was evaluated with v2, s2 and I2.
Potential causes of heterogeneity were explored by carry-
ing out sensitivity analyses. Subgroup analysis was made to
further explore potential heterogeneity among studies
according to population mean age (<30, 30 years), mean
BMI (<25, 25 kg/m2), study design (prospective cohort, retro-
spective cohort, cross-sectional), country of publication
according to the International Diabetes Federation (IDF) atlas
[25] (Africa (AFR), Europe (EUR), Middle East and North Amer-
Table 1 – Diagnostic criteria for Gestational Diabetes Mellitus (GDM).
GDM definition
OGTT glucose level at time point (mmol/mol)
GDM criteria Fasting 1 h 2 h 3 h Number of values for diagnosis
ADA 2000–2010 53 100 86 – 2
ADIPS 1998 55 – 80 – 1
CDA 2003 53 106 89 – 2
CDA 2013 53 106 90 – 1
Chinese locala 56 103 86 67 2
DIPSI – – 78 – 1
EASD 1996 60 – 90 – 1
HAPO OR 20 53 106 90 – 1
IADPSG/WHO 2013 51 100 85 – 1
JSOG 56 100 83 – 2
Modified IADPSG 51 – 85 – 1
NICE 56 – 78
NZSSD 2004 55 – 90 – 1
WHO 1999 70 – 78 – 1
WHO 2006 61 – 78 – 1
ADA = American Diabetes Association. ADIPS = Australasian Diabetes in Pregnancy Society. CDA = Canadian Diabetes Association.
DIPSI = Diabetes in Pregnancy Study Group India. EASD = European Association for the Study of Diabetes. HAPO = Hyperglycemia and Adverse
Pregnancy Outcome. IADPSG = International Association of Diabetes and Pregnancy Study Groups. JSOG = Japan Society of Obstetrics and
Gynecology. NICE = National Institute for Health and Care Excellence. NZSSD = New Zealand Society for the Study of Diabetes. WHO = World
Health Organization.
a The Obstetrics and Gynecology Subcommittee of the Chinese Medical Association 2014.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 2 ( 2 0 2 1 ) 1 0 8 6 4 2 3ica (MENA), South and Central America (SACA), South East
Asia (SEA), Western Pacific (WP), North America and Carib-
bean (NAC)), screening method (2 stepped polycose (50 g
one-hour glucose test  7.8 mmol/L), risk factors, universal
OGTT), early screening (yes/no, if not stated otherwise), use
of modified IADPSG criteria (OGTT without one-hour value.
Yes/no). In these analyses, we used 99% CIs to reduce the
potential for chance differences arising from multiple testing.
The possibility of publication bias was assessed by visual
inspection of funnel plot and Egger’s test. The nonparametric
‘‘trim and fill” method was used to identify and correct any
funnel plot asymmetry.
RRs were unadjusted because they were calculated from
raw data. All the analyses were performed in Stata 16.0 (Sta-
taCorp LLC, College Station, Texas, USA). A two-sided p-
value < 0.05 was considered statistically significant.
3. Results
Overall, 4 312 of 6 889 identified records through a database
search were screened (Fig. 1). The 31 studies included in the
meta-analysis consisted of 136 705 pregnant women of whom
20 127 (147%) had GDM according to the IADPSG criteria and
11 577 (85%) using the old GDM criteria.
The studies were published 1991–2016 with 20 (645%) ret-
rospective cohorts [26–45], seven (226%) prospective cohorts
[46–52] and four (129%) cross-sectional [53–56] studies. Thir-
teen (419%) of the studies were conducted in WP (six Aus-
tralian, four Chinese, one Japanese, One Thai, one
Vietnamese) and seven (226%) in EUR (two English, one Croa-
tian, one Norwegian, one Hungarian, one Irish, one Turkish).
SEA (three Indian, one Nepali, one Sri Lankan), MENA (two
Emirati, one Saudi), AFR (one South African, one Nigerian) ,SCA (one Brazilian) accounted for five (161%), three (97%),
two (65%) and one (32%) study respectively. No studies were
included from NAC. The prevalence of GDM was 188% in WP,
17.2% in AFR, 414% in MENA, 167% in SEA, 173% EUR, 180%
SCA with the IADPSG criteria compared to 98%, 55%, 181%,
93%, 103% and 71% with the old criteria respectively.
Twenty-seven (871%) studies used universal screening
with diagnostic 75 g OGTT compared to three (97%) using
2-step polycose test and one (32%) risk factor screening.
The most widely used old GDM criteria were WHO 1999 in
13 (419%), Australasian Diabetes in Pregnancy Society
(ADIPS) 1999 in six (194%), American Diabetes Association
(ADA) 2000–10 in five (161%) and National Institute for
Health and Care Excellence (NICE) in two (65%) studies.
Hyperglycemia and Adverse Pregnancy Outcome (HAPO)
2.0, Diabetes in Pregnancy Study Group India (DIPSI), WHO
2006, Japan Society of Obstetrics and Gynecology (JSOG)
and Chinese local criteria were used in one study (32%) each
(Table 2). Fourteen (438%) of the studies showed high qual-
ity, and 18 (563%) moderate. Details of the quality assess-
ment of included studies are presented in Supplementary
Tables 2 and 3.
The overall RR for GDM according to the IADPSG criteria
compared to old GDM criteria was 175 (95% CI 153–201), with
evidence of heterogeneity in the risk estimate (I2 = 973%,
v2 = 13793, df = 30, p < 00001) (Fig. 2).
Generally, although no asymmetry was found, there was a
high variance in the effect estimates between studies, espe-
cially in studies with larger effect size (Fig. 3). There was no
substantial publication bias for meta-analyses based on the
Egger test (Supplementary Table 4).
Potential sources of heterogeneity in the subgroup analy-
sis by study and participant’s characteristics for GDM when
Table 2 – Study characteristics.
Study type, publication, Country, study year/s Total women studied Mean age (years;
SD or 95% CI)
Mean BMI (kg/m2;
years; SD or 95% CI)
Screening method Early screening Prevalence
New criteria/Old criteria (%)
Criteria used in the study Quality scale (high-low)
Adam et al. (2017) [46] Prospective cohort, South Africa. 554 272 266 Universal OGTTa No 258/72 IADPSG, WHO 99, NICE Moderate
Agarwal et al. (2015) [26] Retrospective cohort, United Arab
Emirates, 2012
2337 298 (58) .. Universal OGTTa No 453/245 IADPSG, WHO 99,
ADA 00–10, ADIPS 98,
CDA 13, CDA 03,
NZSSD, EASD 96
Moderate
Agarwal et al. (2010) [27] Retrospective cohort, United Arab Emirates,
2003–2008
10,283 283 (61) .. Universal OGTTa No 377/129 IADPSG, ADA 00-10 Moderate
Alfadhli et al. (2015) [47] Prospective cohort, Saudi Arabia, 2011–2012 277 308 (62) 295 (63) Universal OGTTa No 415/170 IADPSG, ADA 00-10 High
Arora et al. (2015) [53] Cross sectional, India, 2009–2012 5100 215 (33) 242 (44) Universal OGTTa No 349/90 Modified IADPSGd, WHO 99 Moderate
Bhavadharini et al. (2016) [28] Retrospective cohort, India, 2013–2014 1774 256 (39) 242 (47) Universal OGTTa Yes 185/146 IADPSG, WHO 99 High
Cheung et al. (2017) [29] Retrospective cohort, Australia, 2014–2016 6175 .. 251 (56) Universal OGTTa No 178/150 IADPSG, ADIPS 98 High
Dahanayaka et al. (2012) [54] Cross sectional, Sri Lanka. 405 273 (54) .. Universal OGTTa No 89/72 IADPSG, WHO 99 High
Djelmis et al. (2016) [30] Retrospective cohort, Croatia, 2012–2014 4646 309 (49) 24.2 (46) Universal OGTTa No 231/178 IADPSG, NICE Moderate
Fukatsu et al. (2017) [31] Retrospective cohort, Japan, 2006–2010 452 341 (45) 245 (56) Risk factorsb No 294/124 IADPSG, JSOG Moderate
Gilder et al. (2014) [48] Prospective cohort, Thailand, 2011–2012 228 263 (65) 233 Universal OGTTa No 101/66 IADPSG, WHO 99, HAPO OR 2.0 Moderate
Hanna et al. (2017) [32] Retrospective cohort, England, 2010–2013 6930 285 (56) .. Universal OGTTa No 137/97 Modified IADPSGd, WHO 99, NICE Moderate
Jenum et al. (2012) [33] Retrospective cohort, Norway, 2008–2010 759 299 (48) 246 (48) Universal OGTTa No 315/130 Modifiedp IADPSG, WHO 99 High
Kun et al. (2011) [34] Retrospective cohort, Hungary, 2000 1835 275 (48) 234 (45) Universal OGTTa No 166/87 Modified IADPSGd, WHO 99 High
Laafira et al. (2015) [35] Retrospective cohort, Australia, 2011–2014 3571 300 (57) 275 (72) Universal OGTTa No 157/130 Modified IADPSGd, ADIPS 98 Moderate
Leng et al. (2015) [49] Prospective cohort, China, 2010–2012 17,808 285 (28) 223 (34) 2 stepped, polycosec No 77/68 IADPSG, WHO 99 High
Meek et al. (2015) [36] Retrospective cohort, England, 2004–2008 25,543 307 (306-308) 247 (246-248) 2 stepped, polycosec Yes 46/41 IADPSG, NICE High
Moses et al. (2011) [50] Prospective cohort, Australia, 2010 1275 299 .. Universal OGTTa No 130/96 IADPSG, ADIPS 98 High
Moses et al. (2016) [37] Retrospective cohort, Australia, 2012–2014 7180 .. .. Universal OGTTa Yes 127/66 IADPSG, HAPO OR 2.0 Moderate
O’Sullivan et al. (2011) [38] Retrospective cohort, Irland, 2006–2009 5500 315 (55) 269 (51) Universal OGTTa No 124/95 IADPSG, WHO 06 Moderate
Olagbuji et al. (2015) [51] Prospective cohort, Nigeria, 2012–2014 1059 307 (44) 281 (79) Universal OGTTa No 86/38 IADPSG, WHO 99 Moderate
Seshiah et al. (2012) [39] Retrospective cohort, India, 2009–2010 1463 236 (33) 215 (41) Universal OGTTa No 146/134 IADPSG, DIPSI Moderate
Shang et al. (2014) [41] Retrospective cohort, China, 2012–2013 3083 291 (35) 220 (29) Universal OGTTa Yes 199/80 IADPSG, ADA 00-10 High
Shang et al. (2014) [40] Retrospective cohort, China, 2008–2011 6201 292 (33) .. 2 stepped, polycosec No 109/52 IADPSG, ADA 00-10 Moderate
Sibartie et al. (2015) [52] Prospective cohort, Australia, 2010–2014 10,277 311 (55)e BMI range Universal OGTTa No 35/34 IADPSG, ADIPS 98 High
Thapa et al. (2015) [55] Cross sectional, Nepal, 2009–2010 564 233 (44) .. Universal OGTTa No 66/25 IADPSG, WHO 99 High
Tonguc et al. (2018) [42] Retrospective cohort, Turkey, 2013–2014 320 29 0 (61) 280 (54) Universal OGTTa No 194/91 IADPSG, ADA 00–10 Moderate
Tran et al. (2013) [56] Cross sectional, Vietnam, 2010–2011 2772 282 (48) 206 (27) Universal OGTTa No 204/208 IADPSG, ADA 00-10, ADIPS 98 High
Trujillo et al. (2015) [43] Retrospective cohort, Brazil, 1991–1995 4926 278 (54) 260 (40) Universal OGTTa No 180/71 IADPSG, WHO 99, HAPO OR 2.0, ADA 00-10 High
Wong et al. (2017) [44] Retrospective cohort, Australia, 2015 1725 Age range BMI range Universal OGTTa No 296/148 IADPSG, ADIPS 98 Moderate
Yan et al. (2017) [45] Retrospective cohort, China, 2009–2011 1683 286 (73) 206 (51) Universal OGTTa No 124/55 IADPSG, Local Chinese Moderate
OGTT = Oral Glucose Tolerance Test. ADA = American Diabetes Association. ADIPS = Australasian Diabetes in Pregnancy Society. CDA = Canadian Diabetes Association. DIPSI = Diabetes in Pregnancy
Study Group India. EASD = European Association for the Study of Diabetes. HAPO = Hyperglycemia and Adverse Pregnancy Outcome. IADPSG = International Association of Diabetes and Pregnancy
Study Groups. JSOG = Japan Society of Obstetrics and Gynecology. NICE = National Institute for Health and Care Excellence. NZSSD = New Zealand Society for the Study of Diabetes. WHO = World
Health Organization.
a Universal OGTT: 2-hour 75 g OGTT.
b Risk factors: BMI  25 kg=m2, maternal weight gain, family history DM, glucosuria, HbA1C  5.9%, RBG  5.5 mmol/L during gestation week 8–12 or 24–28, polyhydramnios, fetal body weight  1.5
SD.
c 2-stepped polycose: 1-hour 50 g oral glucose challenge test before OGTT.
d Modified IADPSG: OGTT based on only fasting and 2-hour values, no 1-hour value.
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Fig. 1 – PRISMA diagram of the literature search for systematic review and meta-analysis [21].
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 2 ( 2 0 2 1 ) 1 0 8 6 4 2 5implementing the IADPSG criteria are shown in Fig. 4. No sig-
nificant heterogeneity was seen from subgroup analysis of
maternal age, BMI, study design, screening method,
early screening and use of modified IADPSG criteria.
There was some statistically significant heterogeneity in the
effect estimates when studies were grouped according to
country of publication. Details of statistical heterogeneity in
subgroup analysis are presented in the Supplementary
Table 4.
Post hoc analysis of European descent (EUR and WP, 19
studies) showed a RR of 156 (95% CI 135–182, v2 = 37278,
p < 00001, I2 = 9602) compared 216(95% CI 167–281,
v2 = 33686, p < 00001, I2 = 9743) with the rest of the popu-
lation (MENA, AFR, SEA, SCA, 10 studies).Further analyses on the impact of GDM criteria showed
that the CDA 2003 criteria gave rise to the highest RR 492
(95% CI 412–588) with the DIPSI criteria the lowest RR 109
(95% CI 086–138) (Supplementary Fig. 1).
Sensitivity analysis showed no evidence of one single study
having excessive influence with an RR variability of 170–179,
which is within the confidence interval of the combined RR
153–201. The impact of decision-making was explored by
excluding and/or including studies based on sample size,
methodology and unpublished data. The effect estimate
across the analysis was between 169 and 200. If studies using
the 100 g OGTT (Carpenter Coustan criteria) were included the
RR was 20 (171–233) (Supplementary Table 5). The hetero-
geneity was not reduced with the sensitivity analysis.
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Fig. 2 – Risk of gestational diabetes mellitus (GDM) after implementation of the new GDM criteria compared to old GDM
criteria. Bars indicate 95% CIs.
6 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 2 ( 2 0 2 1 ) 1 0 8 6 4 24. Discussion
The prevalence of GDM in this meta-analysis was 147%
according to the IADPSG criteria and 85% when using the
old GDM criteria. When implementing the new internation-
ally recommended IADPSG criteria we found that overall,
there was a 75% (RR 175 (95% CI 153–201)) increased preva-lence of GDM compared to the old GDM criteria. Although
the overall increase in prevalence was generally similar
throughout sensitivity and subgroup analyses, a larger varia-
tion was seen when data was stratified according to different
old GDM criteria.
The strength of this large meta-analysis is that it included
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Fig. 3 – Funnel plot of 31 studies included in meta-analysis.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 2 ( 2 0 2 1 ) 1 0 8 6 4 2 7intervention and control occurred in the same population in
31 different studies. Potential biases for the outcome, such
as involving only high-risk populations, different screening
methodologies before and after the intervention, having more
than a gap of one year between intervention and control per-
iod, were excluded to reduce clinical and methodological
heterogeneity. Sensitivity analyses revealed a robust effect
estimate. There was consistency in quality and method
throughout the study.
Limitations included the inability to stratify results
according to ethnicity (minority/indigenous) and geography
(rural or urban) due to a shortage of studies addressing these
populations sufficiently. Two studies [28,53] from India men-
tioned the proportion of the population that were rural and
urban. Ethnicity was reported in a variety of groupings. Two
studies [33,35] had satisfactory data on ethnicity. Although
such risk factors for GDM were not analyzed, it is unclear
whether the higher prevalence of diabetes mellitus in indige-
nous [57] or rural [58] populations would have had an effect
on the relative prevalence of GDM when changing the diag-
nostic criteria.
A further limitation was the high statistical heterogeneity
in the overall effect estimate and subgroup analyses were per-
formed to determine potential sources of heterogeneity. How-
ever, the estimates were similar when studies were grouped
according to maternal age, BMI, study design, country of pub-
lication, screening and sampling method, suggesting that
much of the heterogeneity was unexplained. When only
using WHO 99 criteria studies, the effect estimate remained
unchanged, suggesting that the impact on choosing alterna-
tive comparative criteria, when no data on WHO 99 criteria
existed, was limited (Supplementary Fig. 1).
No statistically significant publication bias was observed
in our study, however, our funnel plot reveals that the preci-
sion of the included studies varied. The largest effect estimate
was seen in a medium size study with 1779 women with GDM
using the IADPSG criteria [53].
There are no prior systematic reviews or meta-analyses
quantifying the relative risk for GDM when implementing
the IADPSG criteria. One meta-analysis on the prevalence of
GDM in India including a subgroup analysis of the diagnosticcriteria reported a 198 fold increase when comparing IADPSG
to WHO 99 criteria [59], which is comparable to our findings.
Behboudi-Gandevani et al. reported a 6–11 fold increase in
prevalence when using the IADPSG compared to old GDM cri-
teria in a subgroup analysis investigating the impact of differ-
ent GDM criteria. This study compared a pooled prevalence of
GDM between different population groups with variation in
the risk factors, screening and diagnostic methods for GDM.
The most comparable group to our study used universal
screening with WHO 2006 criteria as a control group showing
a 4 fold increase, but this was not statistically significant [10].
The prevalence of GDM varies substantially worldwide
attributable, at least in part, to the lack of uniformity in
screening and diagnostic criteria. Behboudi-Gandevani et al
reported a pooled wordwide prevalence of 44% (95% CI 43–
44%) regardless of the type of screening threshold categories
and 106% (95% CI 105–106%) when using the IADPSG criteria,
which is lower than our data (85% vs 147%) [10]. McIntyre
et al present the median prevalence with interquartile for
GDM in a literature search from 2005 to 2018 across the
WHO regions. The prevalence in WP was 103% (45–203),
108%(85–311) in AFR, 150%(96–183) in SEA, 61% (18–310)
in EUR, MENA 152% (88–200) and SCA 112 (71–166) [12]
which is comparable to our study. Although our data also
showed the highest prevalence in MENAwhen implementing
the IADPSG criteria, the prevalence in our study was higher
(414%). McIntyre et al presented a median prevalence in
NAC of 70% (65–119) [12], but no studies from this area were
included in our study partly due to 100 g OGTT being widely
used for GDM diagnosis. Although prevalence might vary
between studies, the main outcome, relative increase in
prevalence should remain unaffected.
Previous publications comparing the polycose test with
risk factor screening showed that the polycose test is more
predictive of GDM as a screening test [60,61]. However, our
analyses included too few studies across each screening
methodology to add further to this issue. The IADPSG
approach usually does not involve such screening strategies
and clearly avoids this sensitivity issue.
The increased prevalence of GDM when implementing the
IADPSG criteria and the heterogeneity in our systematic
review and meta-analysis provide an insight into the real
world and its associated clinical diversity. The increase in
GDM prevalence using the IADPSG criteria leads to an
expected increase in GDM prevalence overall, but less than
previously reported. Implementing the IADPSG criteria will
let us move toward homogeneity in reporting GDM preva-
lence. However, our study did not evaluate whether the
implementation of the new GDM criteria led to fewer adverse
outcomes for the women and their children, any health eco-
nomic impact and any psychological effects. Treatment for
GDM compared to routine care has previously been shown
to improve the quality of life with GDM treatment [8]. Health
economic impacts, and workload on frontline teams, are
probably able to be reduced by changing the model of care
[62].
Data availability
The datasets analysed during the current study are avail-
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Fig. 4 – Risk of gestational diabetes mellitus (GDM) after implementation of the new GDM criteria grouped by Age (years), BMI
(kg/m2), study design, country of publication, screening method, use of early screening and sampling method.
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